Glucose/Sodium Chloride Fresenius Kabi

Glucose/Sodium Chloride Fresenius Kabi is an intravenous injection solution containing sodium chloride and glucose monohydrate. It is supplied as a sterile liquid for infusion, intended for use in the European Union market. It provides both electrolyte (sodium chloride) and carbohydrate (glucose) components to support fluid balance and energy needs when administered by healthcare professionals under prescription. It is designed for intravenous administration and classified as a prescription medication.

Glucose/Sodium Chloride injection is used in clinical settings to address fluid and electrolyte deficits and to provide an energy source during intravenous therapy.

- Replenishment of extracellular fluid volume in patients with dehydration or hypovolemia. - Replacement of sodium and chloride losses associated with gastrointestinal drainage, burns, or diuretic therapy. - Provision of a carbohydrate source for patients unable to receive oral nutrition. - Support of perioperative fluid management to maintain hemodynamic stability. - Adjunctive therapy in parenteral nutrition regimens where glucose is required.

Adverse reactions to Glucose/Sodium Chloride injection are generally infrequent, but they may occur and are categorized by frequency and severity.

Common: - Mild local irritation at the infusion site. - Transient hyperglycemia. - Slight increase in serum sodium levels. - Nausea or mild headache.

Serious: - Severe hypernatremia leading to neurologic symptoms. - Anaphylactic or severe allergic reaction. - Fluid overload causing pulmonary edema.

When administering Glucose/Sodium Chloride injection, clinicians should observe several precautions to minimize risk and ensure appropriate use.

- Assess patient’s fluid status and electrolyte balance before initiation. - Monitor serum glucose and sodium concentrations during therapy. - Use caution in patients with renal impairment or congestive heart failure. - Adjust infusion rate in individuals at risk for rapid shifts in osmolarity. - Avoid administration to patients with known hypersensitivity to any component of the solution. - Consider compatibility with other intravenous medications before co‑infusion.

Glucose/Sodium Chloride injection may interact with other drugs; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent administration with hypertonic saline solutions, which may cause excessive sodium load. - Mixing with calcium‑containing solutions that can precipitate insoluble salts.

Use with caution: - Concurrent use of insulin or oral hypoglycemic agents, which may amplify glucose‑lowering effects. - Diuretics that promote sodium loss, requiring close monitoring of electrolyte status. - Blood pressure–lowering agents, as rapid volume expansion may affect hemodynamics.